Finanzen von Relay Therapeutics Inc (RLAY)RLAYRelay Therapeutics Inc

Evaluating the bottom line, Relay Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25949.71%, while the net margin is -23916.29%. These profitability ratios, combined with a Return on Equity (ROE) of -36.77%, provide a clear picture of how effectively RLAY converts its operational activities into shareholder value.

In the context of the broader market, RLAY competes directly with industry leaders such as TNGX and ABCL. With a market capitalization of $3.79B, it holds a significant position in the sector. When comparing efficiency, RLAY's gross margin of 100.00% stands against TNGX's N/A and ABCL's 100.00%. Such benchmarking helps identify whether Relay Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a net loss of 73,291,000 USD in Q1 2026, with a gross margin consistently at 100%.